(Q47746221)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25693889%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

title

Optimizing the glutamatergic challenge model for psychosis, using S+ -ketamine to induce psychomimetic symptoms in healthy volunteers (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25693889%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25693889%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Hendrik Daniël Kleinloog

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25693889%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Anna Uit den Boogaard

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25693889%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Albert Dahan

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25693889%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

René Mooren

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25693889%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Erica Klaassen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25693889%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Jan Freijer

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25693889%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Joop van Gerven

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25693889%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

language of work or name

English

0 references

publication date

17 February 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25693889%20AND%20SRC:MED&resulttype=core&format=json

Journal of Psychopharmacology

1 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25693889%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25693889%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25693889%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

401-413

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25693889%20AND%20SRC:MED&resulttype=core&format=json

Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man.

1 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Low dose ketamine increases prepulse inhibition in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

How can drug discovery for psychiatric disorders be improved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Visual motor co-ordination and dynamic visual acuity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Translating discoveries into medicine: psychiatric drug development in 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

The evolution of drug development in schizophrenia: past issues and future opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Does ketamine mimic aspects of schizophrenic speech?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Biomarkers for the effects of antipsychotic drugs in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Clinical and sensorimotor gating effects of ketamine in normals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Initial phase 2 trial of a nicotinic agonist in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Effect of a subanesthetic dose of ketamine on memory and conscious awareness in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Half a century of antipsychotics and still a central role for dopamine D2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

NMDA antagonist effects on striatal dopamine release: positron emission tomography studies in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Does olanzapine inhibit the psychomimetic effects of Δ⁹-tetrahydrocannabinol?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Interactive effects of subanesthetic ketamine and haloperidol in healthy humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Effects of ketamine in normal and schizophrenic volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Eye tracking dysfunction in schizophrenia: characterization and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Central nervous system effects of haloperidol on THC in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Greater vulnerability to the amnestic effects of ketamine in males.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Neural correlates of S-ketamine induced psychosis during overt continuous verbal fluency

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Effect of subanesthetic ketamine on intrinsic functional brain connectivity: a placebo-controlled functional magnetic resonance imaging study in healthy male volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

ECNP Summit on the future of CNS drug research in Europe 2011: report prepared for ECNP by David Nutt and Guy Goodwin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Modulating sensory gating in healthy volunteers: the effects of ketamine and haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

The effects of a sub-anaesthetic dose of ketamine on human selective attention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Effects of different subanesthetic doses of (S)-ketamine on neuropsychology, psychopathology, and state of consciousness in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Psychiatric safety of ketamine in psychopharmacology research

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

S(+)-ketamine effect on experimental pain and cardiac output: a population pharmacokinetic-pharmacodynamic modeling study in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Role of glutamate in schizophrenia: integrating excitatory avenues of research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy: a [(123)I]CNS-1261 SPET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Enhanced response to repeated d-amphetamine challenge: evidence for behavioral sensitization in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Estimation of pupil size by digital photography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Vanishing clinical psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082

Effect of intrapulmonary tetrahydrocannabinol administration in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881115570082